<DOC>
	<DOCNO>NCT02217761</DOCNO>
	<brief_summary>The purpose study investigate factor influence pharmacokinetic pharmacodynamic property new antifungal agent , posaconazole Taiwanese patient .</brief_summary>
	<brief_title>Pharmacokinetic Study Patients Receiving Posaconazole Therapy Taiwan</brief_title>
	<detailed_description>Invasive fungal infection ( IFI ) may cause high mortality morbidity immune- compromise patient . Posaconazole , new triazole antifungal agent broad spectrum coverage , approve treatment prophylaxis IFIs . Previous study demonstrate relationship posaconazole plasma concentration efficacy , thus , importance posaconazole therapeutic drug monitoring ( TDM ) gradually accept . However , study find inter- intra-individual variation concentration , phenomenon affect greatly GI function , food intake concomitant medication . Furthermore , 's lack posaconazole TDM study Asian population . The study design describe prescribe pattern posaconazole , study relationship concentration clinical outcomes/ adverse event , identify factor influence plasma concentration , evaluate whether routine TDM need institution .</detailed_description>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Patients receive posaconazole therapy Patients age 13 year old No posaconazole plasma concentration available</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Antifungal Agents</keyword>
</DOC>